Levetiracetam
Product Images NDC 50090-4023

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-4023). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500904023)

Levetiracetam is a medication available in a tablet form. Each tablet contains 1 gram of the active ingredient. This particular package contains 50 tablets with a total of 1600 milligrams.*

FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

The figure shows responder rates in Study 1, with a 250% reduction from baseline. The percentage values range from 0% to 39.6%, and there is a statistical significance when compared with the placebo. The rest of the text contains non-English characters and cannot be used to form a description.*

FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

The text describes a figure, specifically Figure 2, which shows the Responder Rate in Study 2 during a certain period called Period A. The figure displays the percentage of patients who showed a reduction of 250% from the baseline. The percentage of patients who responded is given for three treatment groups: Placebo (N=111), Levetiracetam 1000 mg/day (N=106), and Levetiracetam 2000 mg/day (N=105). One of the percentages is statistically significant versus placebo.*

FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

The figure shows the responder rate (50% reduction from baseline) in Study 4. The placebo group (N=97) had a responder rate of 19.6%, while the levetiracetam group (N=101) had a significantly higher responder rate of 44.6%. The value for the responder rate in the levetiracetam group is 45%, and there is a statistically significant difference between the levetiracetam and placebo groups.*

FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

The figure shows the responder rate of patients aged 1 month to <4 years in Study 5, indicating >50% reduction from baseline. The graph compares the results of patients administered with Levetiracetam and Placebo. The percentage of patients who responded to the treatment is plotted on the Y-axis, while the type of treatment (Levetiracetam or Placebo) is plotted on the X-axis. The results show that Levetiracetam was statistically significant in reducing the rate of responders compared to Placebo.*

FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

The text describes a graph or figure showing the Responder Rate in percentage for patients suffering from PGTC Seizure Frequency per Week. The Responder Rate has been reduced by 250% from Baseline. The study included a Placebo group with 84 patients and a Levetiracetam group with 79 patients. The graph shows that the Levetiracetam group had a statistically significant better response rate as compared to the Placebo group.*

FDA Label Image

Chemical Structure (Levetiracetam Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.